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Abstract: 
In cats with chronic kidney disease (CKD), the most common histopathological 
finding is tubulointerstitial inflammation and fibrosis. However, these changes 
reflect a non-specific response of the kidney to any inciting injury. The risk of 
development of CKD in a patient is likely to reflect genetic predispositions, 
ageing, environmental and individual factors that influence decline in renal 
function over the course of a cat’s life. However, there is still relatively little 
information about exactly which risk factors predispose a cat to develop CKD 
and these will be explored. Whilst many cats diagnosed with CKD have stable 
disease for many years, some cats show overtly progressive disease. From the 
human and experimental literature the pathophysiological processes 
underpinning this progression have been elucidated and include haemodynamic 
alterations after loss of functional renal mass, activation of the renin-angiotensin 
aldosterone system, proteinuria, alteration in phosphorus homeostasis, hypoxia 
and oxidative stress. Many of these pathophysiological mechanisms are likely to 
translate to feline CKD and an understanding of their role in the progression of 
disease gives the opportunity for therapeutic intervention.  
 
Key points: 
 
 Chronic kidney disease (CKD) is a common condition in mature, 
senior and geriatric cats, which is characterized by tubulointerstitial 
inflammation and fibrosis.  
 CKD is a complex disease condition, the development of which is 
likely to be influenced by genetic, environmental and individual 
patient factors.  
 Factors that have been associated with progressive CKD from 
experimental and human medicine include haemodynamic 
adaptations to renal injury, systemic hypertension, activation of the 
renin-angiotensin aldosterone system, proteinuria, 
hyperphosphatemia hypoxia and oxidative stress.  
 Irrespective of the inciting injury, the common pathway for the 
progression of renal injury is via inflammation and fibrosis.  
 Understanding factors associated with progression of disease gives 
potential for therapeutic intervention, which may slow advancing 
disease. 
 
Introduction: Chronic kidney disease (CKD) is a common condition identified in 
cats at both general practice and referral level. The term CKD is used to imply 
alteration in structure or function of the kidney that has occurred over a period 
of time, typically 3 months. A number of different underlying renal diseases can 
affect the feline kidney, some localizing to a particular region of the kidney, some 
being congenital and others acquired in origin. At least initially, not all of these 
conditions will result in azotemia and yet they may still fulfill the criteria of CKD 
e.g. altered tubular function or primary glomerular disease. However, when 
examining post-mortem tissue from geriatric cats diagnosed with CKD in a first-
opinion setting, where the predominant breed examined was either the domestic 
short or longhair, then specific renal diseases accounted for only ~16% of all 
CKD.1 The most common histopathological finding was non-specific 
tubulointerstitial inflammation, fibrosis and mineralization referred to as 
tubulointerstitial nephritis.1-4 The development and progression of these lesions 
will be the focus of this article but given the limited response of the kidney to an 
inciting injury, tubulointerstitial inflammation and fibrosis is a common end 
pathology for many primary renal diseases.  
 
Early studies suggested that approximately 15-30% of cats over the age of 15 
years show evidence of CKD.5 However, markers of GFR used in clinical practice 
are insensitive for the detection of early decline in renal function (Chapters 1 and 
2) and it is appreciated that substantial renal pathology may be present by the 
time a patient develops azotemic CKD.2 Such patients may have other evidence 
that points to the clinical diagnosis of CKD without the requirement for renal 
biopsy e.g. persistently inadequately concentrated urine or abnormalities 
identified with diagnostic imaging of the kidney. These patients are recognized 
within the International Renal Interest Society (IRIS) staging system as having 
non-azotemic stage 1 or 2 CKD. Recent studies that include these early diagnosed 
patients suggest that the prevalence of CKD is much higher, and in the study by 
Marino and colleagues 80% of cats > 15 years were defined as having CKD.6 
 
Aetiology of feline chronic kidney disease: 
The underlying aetiology of feline CKD, where the primary histopathological 
finding is tubulointerstitial nephritis, is poorly understood. CKD should be 
considered as a complex disease that is likely to be influenced by genetic, 
individual, and environmental factors.  
Ageing and the kidney 
In human medicine it is known that GFR declines with age as a consequence of 
renal structural change, tubular dysfunction and a decrease in the number of 
functioning nephrons. These changes begin around the age of 30-40 years but 
accelerate after the age of 50-60 years.7-9 Decline in GFR in humans has been 
reported to be between 0.4 and 1.02 ml/min/year and CKD to be present in 
approximately 35% of the general population over the age of 70 years using 
current criteria.7,10 This has lead studies to question whether the criteria that are 
used for the diagnosis and staging of CKD (Kidney Disease Outcomes Quality 
Initiative; KDOQI guidelines) should be applied equally to young and old alike 
given that decrease in GFR may be ‘normal’ in old age and the mortality risk 
associated with a given stage of CKD may be different between young and older 
age groups. It can therefore be debated whether a diagnosis of CKD in the elderly 
truly represents a disease process rather than part of normal ageing.10-13 
Although CKD is most often identified in cats over the age of 12 years, there is 
evidence that tubulointerstitial inflammation may be identified in the renal 
parenchyma of young cats that have died for other reasons and as such it has 
been proposed that the development of CKD may also be part of a normal aging 
process in cats.14 
 
Ageing is a programmed biological process, which is regulated by many genes. It 
results in impairment to normal adaptive responses and homeostatic 
mechanisms that makes organs susceptible to either internal or external 
stressors.10 Transciptional differences have been identified between the young 
and the old affecting many genes.10 However, there are certain genes, e.g. Klotho 
(an ageing suppressor gene encoding for alpha-Klotho) and SIRT 1 (encoding for 
sirtuin-1 which is a NAD-dependent histone deacetylase involved in cellular 
regulation), which may be of particular interest.10,15 Klotho was first identified in 
1997 in a mutant mouse strain that demonstrated an ageing phenotype and 
shortened lifespan.16 Subsequently it’s concurrent role in phosphorus 
homeostasis and kidney disease has made it a gene and molecule of particular 
interest with relation to CKD and declining renal function with age.17,18  
 
A number of different mechanisms can contribute to age related organ 
dysfunction including mitochondrial injury, telomere shortening, oxidative 
stress, pro-fibrogenic and pro-inflammatory mediators and an imbalance 
between cell repair and proliferation versus apoptosis and cell death (Figure 1). 
However, many of these mechanisms occur not only during ageing but also as 
part of an organ’s response to injury and as part of a healing process. Cellular 
senescence occurs as part of the aging process (replicative senescence) and 
refers to the situation where cells enter a state of replication and growth 
arrest.11 Such cells remain viable but show an altered morphology including 
increased expression of senescence associated β-galactosidaes (SABG), 
accumulation of lipofuscin granules, lack of response to mitogenic stimuli and in 
some species, e.g. humans, replicative senescence is associated with telomere 
shortening and reduced telomerase activity.10 Cellular senescence can also be 
stimulated by a number of physiologic stressors, e.g. oxidative stress, 
mitochondrial damage, renin-angiotensin system (RAAS) activation, which is 
referred to as stress-induced premature senescence (SIPS). These stressors may 
also contribute to telomere shortening.11 Cellular senescence markers e.g. 
telomere shortening, SABG and P16INK4a (involved in the SIPS pathway), have 
been shown to correlate with renal ageing in humans although there are inter-
species differences.19-21 Senescent cells have altered secretion of products such 
as transforming growth factor-β (TGF β), epithelial growth factor, insulin like 
growth factor and vascular endothelial growth factor (VEGF).   The net effect of 
these changes is reduced capacity of the kidney to respond to repair and 
withstand normal stressors and also reducing it’s ability to recover from periods 
of, for example, ischemic injury and promotion of inflammation and fibrosis.11 
 
In cats, preliminary data evaluating telomere shortening supports the concept of 
an ageing process. Telomere length has been evaluated in renal (proximal (PTC) 
and distal tubule), hepatic and dermal tissue from cats with CKD, geriatric and 
young control cats by telomere flurescence in-situ hybridization with 
immunostaining (TELI-FISH) in addition to evaluation of SABG.22 Telomere 
shortening was evident in PTC of geriatric cats with CKD compared to age 
matched and young controls despite no difference in telomere length in skin or 
liver from the same groups.22 Significantly increased staining for SABG was also 
found in renal tissue from cats with CKD compared to the young controls 
although the difference between geriatric control cats was not significant.22 It 
therefore seems feasible that aging may be a component of the decline in renal 
function that we see in older cats but it is also likely that other individual and 
environmental factors contribute to an individual’s overall risk of developing 
CKD.  
Association of chronic kidney disease with demographic, environmental 
and individual factors: 
There are relatively few clinical studies that have evaluated phenotypic, 
environmental or lifestyle risk factors for the development of feline CKD. 
However, a recent study indicated that poor body condition, periodontal disease, 
cystitis, being male neutered rather than female spayed and anaesthesia or 
documented dehydration in the preceding year were risk factors for CKD.23 It has 
been suggested that certain breeds of cats may be predisposed to CKD e.g. 
Persian, Abyssinian, Siamese, Ragdoll, Maine coon but the current evidence base 
for these breed predispositions is low.5,24,25 Similarly although the study above 
suggested a predisposition in neutered male cats, overall other studies have not 
supported a sex predisposition.  
Concern has previously been raised regarding the role that diet may play in the 
development of CKD in cats. A potassium depleted high protein diet has 
previously been associated with the development of kidney disease whilst a 2 
year study indicated no association between high salt intake and adverse effect 
on renal function in older cats.26,27 A single study has suggested that ad-lib 
feeding and increased ash intake were associated with CKD compared to control 
cats although the study was relatively small.28 The study by Greene and 
colleagues did not support an association between diet and development of CKD 
such that overall evidence is controversial and further work is required.  
There are many interventions that occur over a cat’s lifetime that could impact 
on the future development of CKD; for example exposure to nephrotoxic drugs or 
renal toxins, periods of pre-renal azotemia and the requirement for general 
anaesthesia. Such episodes may reflect periods of undetected acute kidney injury 
(AKI), which may be a stimulus for inflammation and fibrosis (Chapter 3). It can 
be hypothesised that, throughout a cat’s lifetime, serial small AKI events could 
lead to an increased risk of developing CKD.  
One further frequent intervention that has been investigated as a potential 
trigger for the development of CKD is vaccination. For vaccine manufacture, 
feline viruses (Feline Herpes virus-1, calicivirus and panleukopenia virus) are 
initially propagated using an immortal line of feline derived tubular epithelial 
cells, Crandell-Rees feline kidney cells (CRFK). It is impossible for all antigenic 
components of these cells to be extracted during vaccine purification and 
manufacture and therefore exposure to antigenic components may occur. 
Administration of certain vaccines could therefore be hypothesized to stimulate 
antibody production, which may bind feline renal proteins and initiate an 
inflammatory response. This hypothesis was explored in a series of studies 
where cats were exposed to either CRFK cell lysate or FRCVP vaccination.29 
Young cats demonstrated antibody response to both parenteral administration 
of FRCVP vaccines and CRFK cell lysate but there was no histopathological 
evidence of renal disease after 56 weeks of study.29 A follow up study, evaluated 
repeated exposure of previously sensitized cats to CRFK lysate. Although this 
study was small there was evidence of tubulointerstitial inflammation in 3/6 cats 
repeatedly inoculated with the CRFK lysate.30 The antigens have been identified 
as α-enolase and annexin-A2.31 However, to date there have been no published 
epidemiological studies that have evaluated vaccination as a risk factor either for 
the development or progression of CKD and any causality between vaccination 
and naturally occurring CKD remains to be determined.  
Association of the development of chronic kidney disease with concurrent 
disease:  
In human medicine there are a number of disease conditions, which are known 
to increase an individual’s risk of developing CKD e.g. cardiovascular disease, 
diabetes mellitus and systemic hypertension. However, the evidence base for 
concurrent disease influencing the development and progression of CKD in cats 
is much more limited.  
 Cardiovascular and renal disorder: The term cardiorenal syndrome has 
been coined in human medicine to express the relationship that exists 
between cardiovascular and renal disease and to define the situation 
whereby acute or chronic dysfunction in one organ may induce acute or 
chronic dysfunction in the other.32 Both cardiac and renal disease are 
common in cats and therefore these conditions may be diagnosed 
concurrently. However, there has been very little focus on the interplay 
between these two body systems, which depend on many similar 
homeostatic mechanisms. The role that cardiovascular disease plays in 
the development of CKD has not been explored.  
A recent consensus group has been established to consider these issues further 
and to promote research into cardiovascular and renal disorders (CvRD).33 
Potential mechanisms by which CvRD may be detrimental to the kidney include 
cardiac shock, low cardiac output and hypotension resulting in reduced renal 
perfusion, AKI and azotemia, activation of the renin-angiotensin aldosterone 
system (RAAS), systemic arterial thromboembolism resulting in renal infarction 
and passive congestion of the kidney during congestive heart failure. In 
particular, inciting renal injuries that result in ischemia provide an interesting 
link to the development of tubulointerstitial inflammation and fibrosis (See 
Chapter 3).34 
 
Systemic hypertension is a well recognized risk factor in humans for the 
development of CKD. Systemic hypertension is identified in approximately 20% 
of cats diagnosed with CKD and of cats that have evidence of systemic 
hypertension approximately 60% are reported to have underlying azotemic CKD 
at diagnosis.35,36 More recently, a study by Bijsmans and colleagues has 
demonstrated a positive association between age and increasing systolic blood 
pressure (SBP) and an increased risk of hypertension in those cats with CKD 
compared to healthy cats.37 However, in longitudinal population studies, SBP has 
not been associated with the development of azotemia, the survival of cats with 
CKD or having a more progressive phenotype of CKD. The cats in these studies 
diagnosed with systemic hypertension however, were always treated with the 
calcium channel blocker, amlodipine besylate, and therefore the true effect of 
systemic hypertension on the development and/or progression of CKD may have 
been masked.38-40 
 Diabetes mellitus: Unlike in human medicine, to date no association has 
been identified between diabetes mellitus and CKD in cats or the 
development of a diabetic nephropathy, although it remains possible that 
this reflects the relatively shorter life expectancy of diabetic cats 
compared to diabetic humans.23,41  
 Hyperthyroidism: Hyperthyroidism is a common condition in the older 
cat and therefore is often diagnosed concurrently with CKD.42 The effects 
of hyperthyroidism on renal haemodynamics are well documented from 
experimental rodent studies including renal hypertrophy and an increase 
in GFR that is believed to be predominantly the consequence of RAAS 
activation secondary to change in β-adrenoceptor activity.42 
Hyperthyroidism has also been implicated in the progression of renal 
disease, the aetiopathogenesis of which is unresolved, but may relate to 
altered renal haemodynamics, hyperfiltration and the increased 
proteinuria identified in hyperthyroidism.42 Studies have shown that GFR 
declines after treatment of hyperthyroidism in cats and that, depending 
on the modality of therapy, between 15-49% of hyperthyroid cats will be 
revealed to be azotemic after treatment.43,44 However, this is considered 
to be the consequence of return to euthyroid state rather than direct renal 
injury. The relative contribution that being hyperthyroid makes to the 
development or progression of CKD in cats is unknown. Cats with 
hyperthyroidism have been shown to be more markedly proteinuric and 
that this proteinuria resolves with treatment of hyperthyroidism.45 
Proteinuria is present as a consequence of glomerular hypertension and it 
can be hypothesized that this in addition to protein processing by the 
proximal tubular cells (see below) may be detrimental to the kidney. 
However, although proteinuria was significantly associated with all cause 
mortality in hyperthyroid cats it was not associated with development to 
azotemic CKD.46 An alternative mechanism that could enable 
hyperthyroidism to contribute to the development or progression of CKD 
is hyperparathyroidism, alterations in calcium and phosphorus 
homeostasis and the potential for soft tissue, including renal, 
mineralisation. Hyperthyroid cats have been shown to have elevated 
parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) 
concentrations.47 However, neither PTH or FGF23 were significantly 
associated with the development of azotemia in hyperthyroid cats.47 The 
exact role of hyperparathyroidism and disorders of calcium and 
phosphorus homeostasis and their effect on renal disease in 
hyperthyroidism remains to be determined. 
 Upper and lower urinary tract stone disease: Both upper and lower 
urinary tract stone disease are well recognized in the feline literature.48,49 
To date there is no data specifically evaluating the effect of periods of 
urethral obstruction as a risk factor for the future development of CKD in 
cats. However, given that post-renal obstruction is an underlying 
aetiology for AKI it can be hypothesized that any period of urethral 
obstruction is likely to have a detrimental effect on the kidney. Similarly, 
in the past decade we have become increasingly aware in clinical practice 
of cats developing uretero- and nephrolithiasis of which approximately 
98% of cases are related to calcium oxalate stones.48-50 It is easy to 
hypothesize that the acute to chronic injury caused by partial to complete 
ureteral obstruction, may play a role in an individual cat subsequently 
developing CKD. However, cats with upper urinary tract stones are 
typically younger (median age 7 years) than cats with CKD suggesting 
that this is not going to be the aetiopathogenesis for all cats with CKD but 
should certainly be considered in cats that present with CKD at a younger 
age.50 Furthermore, a study by Ross and colleagues evaluated the 
presence of nephroliths as a risk factor for mortality and progression of 
CKD but found no association.51 
 Infectious disease: There has been considerable interest in the potential 
for infectious disease to contribute to the development of CKD although 
evidence for these potential associations is currently poor.  
o Urinary tract infections and pyelonephritis: Cats with CKD are 
at inherent risk of urinary tract infections (UTI) due to reduced 
host defense mechanism. UTI are reported to affect between 17-
33% of cats diagnosed with CKD, a substantial proportion of which 
may present as asymptomatic bactiuria.3,52-54 To date only the 
study by Greene and colleagues has specifically evaluated prior 
episodes of cystitis as a risk factor for CKD in cats although it was 
not possible to separate the specific nature of the cystitis in this 
study e.g. feline lower urinary tract disease versus bacterial 
cystitis. Nevertheless, the presence of bacterial UTI and the 
possibility of ascending infections resulting in either acute or 
chronic pyelonephritis certainly raises concern in relation to acute 
on chronic kidney injury and the progression of CKD. Further work 
is needed to establish the significance of positive urine cultures in 
cats with CKD and the role that symptomatic UTI versus 
asymptomatic bactiuria play in the progression of disease.55 
o Feline immunodeficiency virus: Based on the presence of human 
immunodeficiency associated interstitial nephritis, several studies 
have investigated the potential role of feline immunodeficiency 
virus (FIV). A recent histopathological study indicated that 
approximately 50% of cats experimentally infected with FIV 
demonstrated histopathological lesions common to patients with 
HIV nephritis including mesangial widening, glomerulosclerosis 
and immune mediated glomerulonephritis when compared to 
controls.56 Histopathological lesions were more marked in kidneys 
from naturally affected cats that were also examined and included 
additional lesions such as amyloid deposits and interstitial 
inflammation and fibrosis.56 However, such cats were older than 
the experimentally infected cats and aged matched controls were 
not evaluated in this study.56 To date epidemiological studies have 
not been able to substantiate a clinical association between FIV 
and CKD.57,58 
o Morbillivirus: Several studies have raised interest in a potential 
association between CKD and morbillivirus infection (FmoPV), a 
paramyxovirus identified in cats.59-63 The virus was shown to have 
cytopathic effects in FCRK cell lines and in small numbers of stray 
cats there seemed to be a higher prevalence of tubulointerstitial 
nephritis in the cats that were positive for the feline morbillivirus 
than in negative cats, although little demographic and phenotypic 
data was available for either group.62 FmoPV has also been 
identified in the urine (10%) and blood (6%) of stray cats in a 
study performed in Japan, and at a higher prevalence from renal 
tissue (40%; 4/10) from cats with CKD.64 The prevalence of 
FmoPV detected in urine by RT-PCR in client owned cats was 
higher at ~15%.65 However, the prevalence of this virus in cats 
outside of Japan and China and any true association with the 
development or progression of CKD remains to be determined. 
o Leptospirosis: Exposure of cats to leptospirosis is reported, with 
prevalence ranging from 3-35% depending on population and 
geographic location, although clinically associated disease is rarely 
reported.66-69 Experimental studies suggest that cats are largely 
resistant to acute leptospirosis although reports of clinical cases 
suggests that this is a possibility.67,70 A study by Rodriguez and 
colleagues has compared seropositivity and urinary PCR between 
CKD cats and non-age matched controls.68 Seropositivity was 
significantly different between the two groups (7.2% non-CKD, 
14.9% CKD cats) although PCR results were not.68 However, a 
further study demonstrated no significant difference in sero-
prevalence between azotemic and non-azotemic cats.71 The exact 
role that current or prior exposure to leptospire organisms plays 
in feline CKD therefore requires further study.  
o Bartonellosis: Potential associations have been made between 
Bartonella species infection and a number of different disease 
conditions but so far no association has been identified between 
Bartonellosis and CKD in cats.72 
 
Irrespective of the underlying aetiology and factors that may contribute to the 
development of CKD, it should be considered as a progressive disease. The 
kidney has a limited capacity to respond to an inciting injury with the main 
pathological findings and the end stage pathway being the development of renal 
inflammation and fibrosis. To date it is not completely clear whether there is a 
causal relationship between fibrosis and the development CKD or whether it is 
purely a secondary and reparative response. Nevertheless, an understanding of 
the mechanisms involved in renal inflammation and fibrosis and the factors that 
contribute to the progression of CKD from human and experimental studies is 
important, as there is likely to be translational implication to the cat. If we are 
not able to prevent development of CKD then the greatest opportunities for 
intervention lie in early diagnosis (Chapters 1 and 2) and prevention of 
progression.  
Renal inflammation and fibrosis: the kidney’s response to injury  
Healthy renal interstitium is composed of sparse cells (fibroblasts and dendritic 
cells) embedded in an extracellular matrix which is composed of collagen (I, III, 
VII), fibronectin and extracellular matrix glycoproteins e.g. tenascin. Renal 
fibrosis usually begins with focal areas of inflammation and activation of 
mesenchymal cells in response to an inciting injury, progressing to generate 
expanding areas of fibrosis and scarring.73 However, after injury it can be 
hypothesized that fibrosis may be playing a number of different roles within the 
kidney. Intervention to slow or reduce fibrosis could therefore have either 
negative or positive effects. For example, fibrosis may occur after kidney injury 
when renal structural repair is incomplete with fibrosis acting as an ‘innocent 
filler’.74 Alternatively, fibrosis may appear after injury but interfere with the 
potential for full recovery. In the former scenario, preventing fibrosis would have 
little impact on the course of disease whereas in the latter, preventing fibrosis 
would be important to improve outcome.74 Fibrosis could also be an 
intermediate stage, whereby the presence of fibrosis acts as a scaffold for repair. 
For example, studies of uranyl acetate-induced acute tubular injury suggest that 
myofibroblasts may emerge after tubular damage providing a supportive 
structure and then regress once regeneration is complete.75,76 Again in this 
situation, prevention of fibrosis would be counterproductive. Following on from 
this hypothesis however, the long-term deposition of fibrosis which does not 
regress might be detrimental to the kidney.74 Although fibrosis may be part of 
the normal healing process, in CKD fibrosis may represent a maladapted 
response of the kidney to injury that fails to terminate.77 It is possible that the 
role of fibrosis may differ between types of renal injury. Tools that modulate 
fibrosis and evaluation their effect in different disease models would be required 
to determine whether slowing or preventing fibrosis has clinical benefit.  
 
Renal fibrosis is characterized by an excessive fibrogenic response and 
expansion of extracellular matrix (ECM), which destroys the normal renal tissue. 
Histopathologically this is characterized by excessive accumulation of ECM, loss 
of renal microcirculation, infiltration of mononuclear inflammatory cells, tubular 
atrophy and dilation and mineralization (Figure 2). In the healthy kidney, 
fibroblasts play an important role in the homeostasis of ECM secretion and 
degradation through the production of proteases. However, during fibrosis 
fibroblasts become activated and transform to myofibroblasts and subsequently 
produce excessive quantities of ECM proteins e.g. collagen IV, laminin, 
fibrinonectin, elastins, fibrillins, TGF-β binding proteins, tenascins and 
proteoglycans.  
 
Four major cell types are important for the genesis of progressive renal fibrosis; 
myofibroblasts, inflammatory cells, microvascular endothelial cells (pericytes) 
and tubular epithelial cells.78 
 Myofibroblasts: The origin of myofibroblasts in the kidney has been the 
source of considerable controversy (Figure 3). Based on recent studies 
the main source accounting for over 50% of myofibroblasts is thought to 
be renal fibroblasts.79,80 Renal fibroblasts are found in the interstitium of 
healthy kidneys and are responsible for production of extracellular matrix 
and communicating with endothelial and epithelial cells. Certain sub-
populations of renal fibroblasts are responsible for production of 
erythropoietin (EPO). In fibrosis models (e.g. unilateral ureteral 
obstruction (UUO) and ischaemic reperfusion (IR) injury), resident renal 
fibroblasts and EPO producing fibroblasts undergo a process of 
transformation to myofibroblasts (Figure 3).74 
 
Pericytes are contractile cells that wrap around microvessels and arise 
from mesenchymal origin.81 They play a critical role in the stability and 
integrity of microvessels and are able to control microcirculation by 
regulating capillary diameter and hence vascular tone.81,82 In response to 
injury, pericytes detach, migrate to the interstitial space and transform 
into myofibroblasts (Figure 2). Pericytes transformation has been 
demonstrated in experimental models of UUO and IR .83,84 
 
Myofibroblasts may also originate from fibrocytes (bone marrow derived 
myeloid precursor cells) with recent studies suggesting that fibrocytes 
account for approximately 35% of myofibroblast production.74,80 Early 
studies suggested that local renal cells including tubular epithelium might 
also undergo either epithelial mesenchymal transition (EMT) and 
contribute to the myofibroblast population.85,86 However, conflicting 
studies have been published using in-vivo data and EMT is likely to 
represent only a very small (<5%) component of myofibroblast 
production.80 Endothelial cells are also capable of endothelial-
mesechymal transition with a recent study suggestion they account for 
approximately 10% of myofibroblast production (Figure 3).87,88 
Myofibroblasts have the characteristics of both fibroblasts and smooth 
muscle cells. Key features include expression of alpha smooth muscle 
actin (α-SMA) and vimentin (intermediate filament protein), abundant 
rough endoplasmic reticulum and their ability to secrete pericellular 
matrix containing collagen and glycosaminoglycans. The recruitment and 
transdifferentiation of precursors to myofibroblasts can be activated by 
both local and circulating factors.  Important stimuli include autocrine 
and paracrine growth factors (e.g. TGF-β, platelet derived growth factor 
(PDGF), VEGF, connective tissue growth factor (CTGF) of which perhaps 
the most important is TGF-β. TGF-β production can be stimulated by 
many factors recognized to promote renal injury including RAAS, 
proteinuria, increased single nephron GFR (SNGFR) and oxidative 
stress.89-93 Other stimuli for the activation of myofibroblasts include 
direct interaction with leukocytes/macrophages (see below) and tubular 
epithelial cells (see below) and local environmental stimuli such as 
hypoxia and hyperglycemia. 
 Inflammatory cells: Inflammatory cells, particularly macrophages, play 
an important role in inflammation, tissue repair and fibrosis. Sub-
populations of macrophages may be responsible for production of 
inflammatory mediators, for example IL1β, TNF-α, chemokines 
(Monocyte Chemotactic Protein-1; MCP1) which recruit further 
inflammatory cells, increase production of TGF-β and PDGF which 
promote myofibroblast activation.77 It has also been speculated that 
monocytes from the circulation may enter renal tissue and differentiate 
into fibrocytes (Figure 2). However, the evidence base for this is largely 
based on cell culture systems.74,94,95 
 Pericytes: The role of pericytes differentiating to form myofibroblasts 
has been described above. However, pericytes are also important for 
vascular stability. The loss of pericytes, as they transform to 
myofibroblasts, contributes to loss of the interstitial capillary network, 
otherwise known as peritubular capillary rarefaction and may play a 
major role in the development of hypoxia, oxidative stress and 
progressive tubular cellular injury and fibrosis.77,78,81,96 Histological 
studies evaluating human kidney tissue have demonstrated that areas of 
renal fibrosis and reduced peri-tubular capillary density located 
together.97,98 Hypoxia is a recognized final common pathway for the 
progression of CKD (see below).99,100 In addition, increase in permeability 
of microvasculature and leakage of plasma proteins such as fibrinogen 
and albumin into the interstitium may trigger an inflammatory 
response.101 
 Tubular epithelial cells: Tubular epithelial cells have a number of roles 
in renal fibrosis. Early in the course of the disease injured tubular 
epithelial cells may be a source of inflammatory mediators, e.g. cytokines 
and chemokines (IL6, MCP-1, tumor necrosis factor-α) which recruit and 
activate inflammatory cells and promote differentiation of fibroblasts to 
myofibroblasts.102 A study by Yang and colleagues demonstrated that 
tubular epithelial cell cycle arrest in response to toxic, obstructive and 
ischemic injury resulted in the development of fibrosis.103 In response to 
injury, tubular cells may also increase production of growth factors (e.g. 
TGF- β, PDGF, fibroblast growth factors (FGF)) and reactive oxygen 
species (ROS). When secreted either via the paracellular route or to the 
basolateral membrane into the tubulointerstitium these factors all have 
have pro-fibrogenic effects.74,78 Urinary complement factors and 
cytokines and protein handling by the tubular cells have also been 
implicated (see below) as stimuli for the release of pro-inflammatory and 
pro-fibrotic mediators from tubular cells.78,104 Later in the disease 
process, lack of regeneration and loss of tubular epithelial cells may 
contribute to progression of disease and loss of nephrons.  
 
Evidence of fibrosis in feline chronic kidney disease: 
The main histopathological finding reported in older cats with CKD is 
tubulointerstitial inflammation and fibrosis.3,4 In human medicine, even in 
patients with primary glomerular disease, it is tubulointerstitial lesions that 
correlate most strongly with renal function. Recently feline studies have 
compared histopathological findings with stage of kidney disease and identified 
that the severity of tubular degeneration, interstitial inflammation, fibrosis and 
glomerulosclerosis was more marked in the later IRIS stages of CKD.2 In a study 
by Chakrabarti and colleagues, fibrosis was the only histopathological finding 
that significantly correlated with severity of azotemia and IRIS stage.1 To date 
two studies have specifically evaluated myofibroblast recruitment in cats with 
CKD.105,106 The presence of myofibroblasts in feline renal tissue, identified by the 
markers αSMA and tubular and interstitial vimentin, correlated positively with 
both fibrosis and plasma creatinine concentration.106 Expression of αSMA and 
fibronectin were significantly higher in cats with tubulointerstitial nephritis 
particularly in the peri-glomerular and peri-tubular areas and were associated 
with severity of azotemia.105 It was also evident that αSMA was expressed at 
earlier stages of tubulointersitital nephritis and in some apparently prior to the 
deposition of ECM.105 
A limited number of feline studies have also evaluated some of the inflammatory 
markers that may be stimuli for fibrosis and inflammation including TGF-β. 
Preliminary studies support increased urinary TGF-β in cats with CKD compared 
to controls and a positive correlation between urinary TGF-β and azotemia.107,108 
However, conflicting studies evaluating active rather than total urinary TGF-β1 
found no significant difference between non-azotemic geriatric cats, non-
azotemic cats that progressed to develop azotemia and azotemic cats. However, 
there was a trend towards increasing active urinary TGF-β in cats that developed 
azotemia and were monitored longitudinally.109 A study by Habenicht and 
colleagues investigated urinary concentrations of IL8 and MCP-1 as ratios to 
urine creatinine as potential markers of renal inflammation and injury. No 
significant difference in MCP-1:creatinine ratio could be detected although IL8: 
creatinine ratio were significantly higher in cats with CKD than control cats.107 A 
shortfall of these studies is that histopathology was not routinely available 
although in other species studies support that the correlation between urinary 
cytokine levels and renal inflammation is strong.110 
Transglutaminase 2 (TG-2) has recently been investigated in cats. TG-2 is a 
calcium dependent cross-linking enzyme from the transglutaminase family, 
which plays an important role in stabilizing extracellular matrix thereby 
promoting extracellular matrix deposition and resistance to degradation. There 
is a strong relationship between TG-2 expression and renal fibrosis in humans 
with CKD and also rodent models.111,112 This has recently been extrapolated to 
the cat where TG-2 activity was positively correlated with renal histopathology 
scoring, plasma creatinine, phosphate and urea concentrations.113 
Together these findings begin to support the importance of fibrosis in the 
pathogenesis of CKD although the further work is required to determine whether 
fibrosis is detrimental and whether modulating fibrotic pathways holds any 
clinical benefit.  
 
Mechanisms of progression and maladaptive repair in chronic kidney 
disease:  
In clinical practice, many cats with CKD remain stable for many years. Median 
survival time of cats with azotemic IRIS stage 2, 3 and 4 CKD have been reported 
as 1151, 778 and 103 days respectively although there is considerable inter-
individual variability and survival times reported are potentially affected by the 
modalities of therapy, interventions and resources available.24,38 However, 
ultimately some cats do demonstrate progressive disease although the time 
point at which that progression occurs is often unpredictable.114 In one study 
29% of cats with IRIS stage 2 disease and 63% of IRIS stage 3 CKD cats 
progressed to IRIS stage 4 before death.40 Epidemiological studies have 
evaluated factors associated with the development of azotemia, survival of cats 
with CKD and also demonstrating a more progressive phenotype of CKD.24,38-
40,115-117 From the experimental and human literature there are a number of key 
pathophysiological mechanisms which have been implicated in both the 
development and progression of CKD. An understanding of these mechanisms is 
important not only because many may be applicable and translated to feline CKD 
but also because they provide potential targets for therapy in order to slow 
disease progression.  
 
Hemodynamic adaptations:  
In the 1980’s, experimental rodent studies were performed that indicated that 
there was a haemoadaptive response that occurred as a consequence of nephron 
loss and which resulted in glomerular hypertrophy, hypertension and 
hyperfiltration. The net effect of these haemodynamic alterations was 
maintaining and increasing single nephron GFR (SNGFR) in order to preserve 
renal function. However, although initially beneficial in terms of maintaining 
total GFR, ultimately these adaptations were detrimental and a critical point 
would be reached where self-perpetuating loss of further nephrons would result 
in progression of disease.  
There is evidence from experimental feline studies that similar haemodynamic 
and structural adaptations occur in cats. Early feline renal mass reduction 
studies documented histopathological evidence of glomerular lesions, fibrosis 
and mineralization and yet when followed over a year, these cats did not 
demonstrate the continued progressive decline in GFR that would be anticipated 
from the rodent studies. Micropuncture studies in cats showed that in response 
to renal mass reduction there was evidence of dilation of pre-glomerular afferent 
arterioles, increase in glomerular capillary pressure and as a consequence 
increased effective filtration pressure and SNGFR. Glomerular hypertrophy with 
a secondary increase in ultrafiltration coefficient, mesangial matrix expansion 
and increased proteinuria were also observed. Cats were therefore documented 
to show similar haemoadaptive and structural changes to those occurring in 
rodent models although the changes were, to some extent, dependent on the 
degree of renal mass reduction. Thus, it has been hypothesized that the 
predisposition of an individual to progressive CKD may be a balance between 
adaptive mechanisms preserving GFR versus the development of structural 
lesions that advance disease.  
 
The role that the haemoadaptive and structural glomerular changes play in 
naturally occurring feline CKD is more difficult to quantify. Studies evaluating 
renal pathology at post-mortem examination have scored glomerular lesions 
included glomerular hypertrophy, glomerulosclerosis and obsolescence (global 
matrix expansion with loss of capillary lumina). Stage 2 CKD cats demonstrated 
significantly increased glomerular volume compared to non-azotemic control 
cats where as in stage 3 and 4 CKD cats glomerular volume was closer to the 
control population. It was hypothesized that this could be explained if 
glomerular hypertrophy occurring earlier in the course of CKD as an adaptive 
process, subsequently became maladaptive resulting in glomerulosclerosis and 
obsolescence. 
 
 
Activation of the renin-angiotensin-aldosterone system: 
It is widely accepted that the RAAS is activated in CKD and that both systemic 
and tissue specific RAAS systems exist. The kidney contains all the necessary 
components for local RAAS activation and indeed renal tissue concentrations of 
angiotensin II (Ang II) are reported to be significantly higher than plasma 
concentrations.118,119 As such, quantification of plasma components of RAAS does 
not necessarily translate to the degree of activation of RAAS within the kidney.120 
RAAS is particularly important as a modulator of blood pressure and fluid 
balance through alteration in sodium and water homeostasis as well as being 
integral to intrarenal haemodynamics and glomerular filtration. Traditionally, 
the RAAS pathway terminates with conversion of Ang I by angiotensin 
converting enzyme (ACE) or alternative pathways (e.g. chymase) to Ang II. Ang II 
mediates its effects predominantly via the type 1 (AT1) receptor which has a 
wide distribution throughout the kidney although type 2 receptors (AT2) are 
present albeit with a more limited distribution.118 However, it is now recognized 
that a number of further products of both Ang I and Ang II may play important 
regulatory roles (e.g. Ang (1-7)/Mas and Ang IV/AT4 pathways) and may have 
impact in the pathogenesis of CKD (Figure 4).118,121,122 
 
Ang II in particular has been highlighted as an important mediator in the 
progression of CKD. It acts as a potent vasoconstrictor contributing to the 
development of glomerular hypertension and hyperfiltration and that it may 
modulate the permeability of the glomerular filtration barrier at least partly by 
altering podocyte interactions.123-125 Therefore Ang II may not only promote 
renal injury through sustained glomerular hypertension and development of 
glomerulosclerosis but also by promoting proteinuria which itself may be 
detrimental to the kidney (Figure 4; see below).126 Ang II also has direct 
fibroproliferative and inflammatory effects by increasing transcription and 
production of inflammatory and profibrogenic molecules including TGFβ hence 
promoting myofibroblast transformation and fibrosis (Figure 4).92 Ang II may 
play a role in the migration and transformation of pericytes to myofibroblasts 
and also the differentiation of circulating fibrocytes to fibroblasts. It has been 
reported to stimulate the production of other growth factors and inflammatory 
mediators from vascular smooth muscle cells, glomerular endothelium and 
mesangial cells (e.g. MCP-1 and RANTES) and is a known activator of NFκβ which 
is a key transcription factor in inflammatory disease stimulating up-regulation of 
genes encoding for pro-inflammatory cytokines.92,127,128 
 
The vasoconstrictive effects of Ang II on the efferent arteriole result in structural 
and functional changes to the peritubular microvasculature (Figure 4). Reduced 
renal oxygenation due to the effects of vasoconstriction may manifest before the 
capillary rarefaction which is identified as part of renal fibrosis.96,129 In 
medullary interstitial cells, Ang II has been shown to activate hypoxia inducible 
factor (HIF-1α) via reactive oxygen species (ROS) generation and in vivo 
medullary interstitial cells from kidneys perfused with Ang II stain positively for 
both HIF-1α and αSMA. These findings together link Ang II to both hypoxia and 
oxidative stress mediated renal fibrosis mechanisms.130 
 Production of aldosterone by the adrenal gland is stimulated by Ang II but may 
itself have pro-fibrotic effects contributing to the pathogenesis of CKD.131 Local 
renal aldosterone production in the renal cortex has been demonstrated in 
rodent models stimulated by Ang II, decreased sodium intake and hyperglycemia 
with the mineralocorticoid receptor identified not only in the distal tubule but 
also in pre-glomerular vasculature, mesangial cells and on fibroblasts.132 In vitro 
studies have shown that mesangial cells significantly increase production of 
TGFβ and fibronectin in response to aldosterone, an effect which can be 
mitigated by the aldosterone antagonist, spironolactone.133 In vivo aldosterone 
infusion in rats significantly increases urinary TGFβ concentration and rats that 
have undergone uninephrectomy and receive aldosterone at the same time as 
AT1 blockade, showed increased expression of TGFβ and collagen, supporting 
that aldosterone is an independent pro-fibrotic mediator.132,134,135 Aldosterone 
has also been shown to increase expression of CTGF and to increase production 
of ROS and inflammatory mediators such as osteopontin, IL6 and IL1.136,137 
Aldosterone may also promote fibroblast growth and proliferation and increase 
expression of PAI-1, which promotes ECM accumulation.131,132 Numerous in vivo 
models of aldosterone inhibition using either the non-selective agent, 
spironolactone, or the specific aldosterone receptor inhibitor, eplenerone, 
demonstrate reduction in glomerulosclerosis and interstitial fibrosis.132 
 
In human medicine, clinical evidence of the role of RAAS in progression of CKD 
comes from studies that have evaluated RAAS blockade. Studies investigating 
both ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) show 
improved outcome when these agents are administered for both diabetic and 
non-diabetic related CKD.138 However, outcomes from these studies have not 
provided the degree of protection that might be anticipated and more recent 
studies have therefore focused on combined ACEi and ARB therapy.138,139 Whilst 
dual therapy may provide further reduction in terms of proteinuria outcome 
measures such as requirement for dialysis, doubling of serum creatinine and 
mortality were not always improved when compared to monotherapy 
particularly for non-proteinuric patients.140 There continues therefore to be 
controversy in terms of optimal therapy for RAAS blockade and whether this 
should be monotherapy, combined fixed dose or individualized ACEi/ARB or 
combined therapy with either aldosterone antagonists or direct renin inhibitors 
(e.g. Aliskiren).141,142 
 
There is relatively little data in the literature evaluating RAAS activation in cats 
with CKD. In experimental feline models of renal mass reduction, significant 
increases in plasma renin activity (PRA) and aldosterone have been 
documented.143-145 In cats that underwent a renal wrap model of renal reduction, 
increased plasma renin, plasma aldosterone, systemic hypertension, proteinuria 
and more marked histopathological changes were reported.144 These findings 
supported RAAS activation in association with this feline experimental model of 
renal mass reduction although this may not be directly translated to naturally 
occurring disease.  
 
A small number of studies have investigated intra-renal RAAS in cats with 
naturally occurring CKD by immunohistochemistry.146-148 The first study by 
Mitani and colleagues evaluated expression of renin and Ang II in feline kidneys. 
Renin was identified in the afferent arteries and Ang II in the proximal tubules 
and mononuclear cells. No association was identified between immunostaining 
of renin with severity of azotemia or histopathological lesions but tubular and 
interstitial Ang II immunostaining correlated with glomerulosclerosis and 
tubulointerstitial inflammation.147 The second study by Mitani and colleagues 
evaluated ACE and ACE2 (mediates production of Ang1-7/Mas pathway) 
expression. ACE was identified predominantly in the proximal tubules whilst 
ACE2 was identified in proximal tubules and weaker staining in the distal 
nephron. Unlike in dogs, there was no association between immunostaining of 
ACE or ACE2 with histopathology scores although sample numbers were 
small.148 Further work and larger studies are required to confirm the association 
between altered expression of these components of RAAS with severity and 
progression of CKD. 
 
Several studies have evaluated plasma components of RAAS in cats with 
naturally occurring CKD, some of which were also hypertensive although results 
have been variable.149-151 A study investigating PRA and aldosterone 
concentration in normotensive azotemic CKD and non-azotemic age matched 
controls found no significant difference between these variables.150 
Experimental feline studies have demonstrated that administration of ACEi 
alters renal haemodynamics and reduces proteinuria with the latter observation 
also been observed in cats with naturally occurring CKD.143,152-154 However, to 
date, the survival advantage that we might anticipate from administration of an 
ACEi has not been demonstrated.152 Clinical equivalency in terms of anti-
proteinuric effect has been documented between the ARB, telmisartan and ACEi 
but results of on-going studies to evaluate the effect of this alternative approach 
on RAAS inhibition and progression of renal disease, renal associated mortality 
and survival are required.155 Overall, given the expanding evidence base from in 
vitro and in vivo experimental studies and from human medicine it seems likely 
that RAAS is an important player in the pathogenesis of feline CKD. However, the 
optimal way to inhibit RAAS to improve outcome remains to be determined.  
 
Systemic hypertension 
Systemic hypertension has been accepted for many decades in human medicine 
as both a factor implicated in the development and the progression of kidney 
disease.156-158 Early experimental rodent models demonstrated that with 
reduced renal function, pre-glomerular vasodilation occurs, permitting over-ride 
of myogenic renal autoregulation, transfer of elevated systemic pressures to the 
glomerular capillaries resulting in glomerular hypertension and 
glomerulosclerosis.159 Histopathological lesions associated with hypertension in 
the kidney include arterosclerosis (arterial intimal thickening, medial 
hypertrophy and duplication of the internal elastic lamina) glomerulosclerosis 
and tubular atrophy which, together in human medicine has been termed 
arterionephrosclerosis. Systemic hypertension and glomerular hypertension has 
also been associated with more marked proteinuria both in experimental rodent 
studies and also in human studies.159,160 
 
The evidence for systemic hypertension contributing to the development or 
progression of feline CKD is unclear. In feline experimental renal mass reduction 
models, systemic hypertension has been associated with histopathological 
changes.144 However, epidemiological studies evaluating factors associated with 
the development of azotemia, the survival of cats with CKD and having a more 
progressive phenotype of CKD have not identified blood pressure as a risk 
factor.38-40 A conflicting factor in all of these studies however, is that cats 
diagnosed with systemic hypertension received anti-hypertensive therapy and 
therefore it is not possible to say whether an association would have been 
identified had untreated cats been included. Cats with systemic hypertension are 
more proteinuric than normotensive cats with equivalent stage of CKD.38 A study 
evaluating factors associated with the survival of cats with systemic 
hypertension evaluated time-averaged blood pressure as a variable giving 
information about degree of control of SBP despite all cats receiving anti-
hypertensive therapy. When cats were divided into quartiles based on their 
timer-averaged SBP those in the upper quartile would still have been considered 
hypertensive despite anti-hypertensive therapy. Never-the-less, only proteinuria 
was significantly associated with survival.36 This raises questions regarding the 
role that systemic hypertension plays in the progression of CKD in cats and 
whether proteinuria might not be the more important factor.  
 
A histopathological study performed by McLeland and colleagues demonstrated 
no difference in severity of vascular lesions (vascular hyperplasia, 
arteriosclerosis, glomerulosclerosis) between hypertensive and normotensive 
cats with naturally occurring CKD.2 However, not all cats in this study had blood 
pressure data available and only 12 cats were diagnosed ante-mortem with 
systemic hypertension. A further study by Chakrabarti and colleagues with blood 
pressure data on 69 cats of which 34 had a diagnosis of systemic hypertension 
also evaluated post-mortem renal pathology.1 The most common hypertension 
associated lesion identified was hyperplastic arteriosclerosis in 3% of 
normotensive and 29% of hypertensive cats and in a multivariable model, mean 
glomerular score and hyperplastic arteriosclerosis were significantly and 
independently associated with time averaged blood pressure.1 As for previous 
studies all cats in this study diagnosed with systemic hypertension received anti-
hypertensive therapy with amlodipine besylate. Nevertheless, the median time 
averaged blood pressure of those cats diagnosed with systemic hypertension 
that demonstrated hyperplastic arteriosclerosis was 171mmHg versus 
152mmHg for those without.1 There was however no association between time-
averaged blood pressure and tubulointersitial inflammation or fibrosis and it is 
difficult to fully interpret the relative effect of blood pressure on these 
histopathological changes versus the effect that administration of amlodipine 
besylate, and afferent arteriolar vasodilation in the face of inadequate blood 
pressure control may have played.  
 
Given the associations that have been made in experimental models of 
hypertension it is reasonable to perceive that the kidney should be considered a 
target organ of systemic hypertension and that appropriate anti-hypertensive 
therapy should be administered accordingly. The role that systemic 
hypertension plays in the progression of CKD remains to be fully determined but 
will prove challenging to evaluate in clinical patients where withholding anti-
hypertensive therapy is not ethically justified. Further studies are also 
warranted to further investigate the role of proteinuria in hypertensive CKD 
patients and to determine whether blood pressure alone or in combination with 
proteinuria would be a better end target.  
 
Proteinuria 
Proteinuria as a consequence of glomerular hypertension, hyperfiltration and 
change in permeselectivity of the glomerular filtration barrier is proposed to 
promote an apoptotic response in tubular cells, alter phenotype of tubular cells 
and contribute to the development of tubulointerstitial inflammation and 
fibrosis.161 In health, filtered proteins are reabsorbed by megalin and cubulin 
mediated endocytosis in the proximal tubules such that the magnitude of 
proteinuria is low.162 However, the process of protein presentation and 
reabsorption by the proximal tubular cells (PTC) is not considered benign.161 
 
For over a decade, there has been evidence from in vitro studies, that proteins 
such as albumin (delipidated or lipidated), immunoglobulin G, and transferrin 
presented to the apical surface of PTC grown in monolayers, upregulate the gene 
expression and production of vasoactive (e.g. endothelin-1), pro-inflammatory 
(MCP-1, RANTES, IL8) and profibrotic factors (e.g. TGFβ). Important 
intermediate mediators have been identified to include NFκβ and ROS and 
megalin has been implicated as a central element linking protein absorption and 
the intracellular pathways that up-regulate gene expression.104,161 Basolateral 
release of these modulators raises the potential that in vivo release would 
potentiate tubulointerstitial inflammation, fibrosis, ECM deposition and 
progression of CKD.  
 
There has been debate regarding exactly which protein molecules are most 
potent in terms of stimulating the inflammatory response and also whether it is 
protein alone or in association with their fatty-acid binding capabilities (e.g. oleic 
and linoleic acid) that is most important in stimulating this response. 
Controversy also exists as to whether the concentrations of proteins used in 
these in vitro studies corresponds to or exceeds the protein concentration of 
ultrafiltrate in vivo and therefore whether results are directly applicability 
particularly to patients with primary tubular disease. Rodent models of 
proteinuria were used to substantiate the role of proteinuria as a stimulus for an 
inflammatory and pro-fibrotic response demonstrating up-regulation of many of 
the inflammatory mediators, e.g. MCP-1, osteopontin, NFκβ, and that these 
changes lead to inflammatory cell recruitment to the tubulointerstitial 
space.163,164 These changes could be abrogated by administration of anti-
proteinuric therapy e.g. ACEi.165,166 
 
Complement activation is a powerful mechanism that can promote both pro-
inflammatory and profibrotic effects either via the classical or alternative 
pathway in the kidney.  There is evidence that both intra-renal and filtered C3, an 
essential factor of both the classical and alternative pathways of complement 
activation, may promote formation and insertion of the C5b-9 membrane attack 
complex.167,168 Studies in proteinuric rodent models have shown that C3 
colocalises to the apical surface of proximal tubular cells in advance of the 
recruitment of inflammatory cells and that these changes can be mitigated by 
administration of ACEi.169 
 
However, other perhaps less well-documented effects of proteins on the PTC 
have been reported. A study by Cao and colleagues indicated that high 
concentrations of albumin presented to PTC stimulated activation of renal 
RAAS.170 Studies support that accumulation of non-esterified fatty acids (NEFA) 
and long chain acyl-co A transported into the tubule bound to albumin may 
accumulate in PTC and be a stimulus for PTC apoptosis.161 In vitro studies using 
cell culture of both human and rodent PTC have shown that albumin can directly 
lead to cellular apoptosis via a caspase-9-mediated mitochondrial pathway and 
that megalin may be an important receptor for this pathway.171,172 In vivo, 
proteinuria has been associated with tubular atrophy and number of apoptotic 
cells but such studies have primarily been performed in disease conditions or 
models of marked proteinuria (e.g. Heymann nephritis and focal segmental 
glomerulosclerosis).173,174 Further work is therefore required to determine the 
significance of this mechanism in primary tubular disease conditions. In human 
medicine numerous studies of both diabetic and non-diabetic CKD have 
demonstrated that proteinuria is associated with faster GFR decline and 
progression to end stage renal disease with evidence that anti-proteinuric 
therapy with an ACEi or ARB can slow this decline although as described above 
dual therapy does not always enhance outcome.138,140 
 
For cats where the primary histopathological lesion is tubulointerstitial 
nephritis, the magunitude of proteinuria is typically low with reported median 
urine protein to creatinine ratios in IRIS stage 2, 3 and 4 CKD being 0.15, 0.22 
and 0.65 respectively.38 In feline CKD, proteinuria has been significantly 
associated with the development of azotemia, having a progressive phenotype of 
CKD, and survival of cats with both CKD and hypertension.36,38-40 In 
histopathological studies of feline kidney tissue at post-mortem, proteinuria has 
been significantly associated with the severity of tubular degeneration, 
inflammation, fibrosis, tubular epithelial cell necrosis and decreased amount of 
normal renal parenchyma.1,2 However, although both ACEi and ARB significantly 
reduce magnitude of proteinuria in cats, the benefit in terms of slowing 
progression of CKD or improving survival has yet to be demonstrated.152,155 On 
the basis of data from experimental studies proteinuria is a key player in the 
pathogenesis of interstitial inflammation and fibrosis. However, further work is 
still required to demonstrate in feline medicine the causative association 
between proteinuria and progression of disease.  
 
Hyperphosphatemia 
Hyperphosphatemia as a consequence of decreased renal excretion has been 
associated with progression of renal disease in human studies.175 Early rodent 
studies showed that diets with excessive phosphorus supplementation 
predisposed to histopathological lesions within the kidney including necrosis of 
the convoluted tubules, calcification and an increase in ECM.176,177 Conversely, 
experimental models of renal disease including the dog have shown that 
phosphate restriction is beneficial in reducing renal injury.178,179 The proposed 
pathogenesis for phosphate being detrimental to the kidney is incompletely 
understood and a number of key mechanisms have been proposed. The most 
frequently cited is that hyperphosphatemia predisposes to renal mineralization, 
which subsequently promotes inflammation and fibrosis. Alternative proposed 
mechanisms include an association between hyperphosphataemia and vascular 
calcification leading to vascular stiffness with subsequent effects on endothelial 
cell function.180-183 These alterations in renal microvascular may be contributory 
to ischemia and hypoxia, which are known stimuli for renal fibrosis (see 
below).183 Phosphate may also affect a number of other key pathways that have 
been associated with renal disease progression including cellular apoptosis, 
cellular senescence and oxidative stress.18,184,185 Extracellular phosphate 
concentrations have also been associated with increased production of 
profibrotic mediators and may have a direct stimulatory effect on RAAS.186-188 
 
There is some evidence supporting the role of phosphorus in the pathogenesis of 
feline CKD. Early studies evaluating phosphate restricted diets showed that cats 
on restricted diets had reduced evidence of renal histopathological lesions 
(calcification, fibrosis and inflammatory cell infiltration) compared to cats on a 
high phosphorus diet.189 Clinical epidemiological studies have identified 
phosphorus to be a risk factor for the survival of cats with CKD and also to be 
associated with a more progressive phenotype of disease.24,40 To date one feline 
study has evaluated post-mortem renal histopathological findings with pre-
mortem phosphate concentrations and identified a significant association with 
interstitial fibrosis but not with renal mineralization.1 More recently 
epidemiological studies have focused on the role of other molecules involved in 
phosphorus homeostasis with both PTH and FGF23 being associated with the 
development and survival of cats with CKD.115-117 Perhaps the most convincing 
evidence that there is likely to be a role for phosphorus homeostasis in the 
progression of CKD comes from the studies that have demonstrated improved 
survival in those cats that are fed a phosphate restricted diet with evidence of 
modulation of these important regulatory hormones.114,190,191 
 
Hypoxia 
Hypoxia has been associated with the development and progression of CKD. A 
number of different potential mechanisms may contribute to hypoxia.192 The 
total blood supply to the kidney is high, representing approximately 20% of 
cardiac output. However, the presence of the counter-current multiplier system 
within the kidney and oxygen diffusion shunt means that the renal medulla 
operates at low oxygen tensions. The high metabolic demand of proximal tubular 
cells means that they may be particularly susceptible to reduced availability of 
oxygen, a mechanism that is used for beneficial effect as a driving factor for the 
production of erythropoeitin. 
In the kidney, afferent arterioles divides to give rise to glomerular capillaries, 
which fuse to become the efferent arteriole. Efferent arterioles enter the 
peritubular complex of capillaries, and provide oxygen and nutrients to the 
tubular cells. Early in the course of CKD alteration in glomerular structure and 
the development of glomerulosclerosis may alter the delivery of blood from the 
glomerulus to peri-tubular capillaries, limiting the blood supply to renal tissue 
(Figure 5). Haemoadaptive alterations, driven at least in part by activation of the 
RAAS (see above) and Ang II, result in relative vasoconstriction of the efferent 
arterioles.129 The benefit of this may be increase in glomerular capillary pressure 
and filtration fraction, but this haemodynamic alteration has secondary 
consequences on the supply of blood and hence oxygen from the efferent 
arteriole to the peritubular capillary network and may result in hypoxia.129 
 Delivery of oxygen to tubular cells is dependent on diffusion. In health, when 
there is little distance between the peritubular capillaries and tubular epithelial 
cells, oxygen is delivered efficiently. However, once there is evidence of 
tubulointerstitial inflammation and fibrosis, the distance for oxygen molecules to 
traverse increases, contributing to hypoxia. Furthermore, loss of interstitial 
microvascular and capillary rarefaction may reduce blood supply to regions of 
the kidney.99,192 
 
As part of the normal physiological response to hypoxia, cells undergo 
adaptations in gene expression in order to try to counteract the effect of low 
oxygen. This response typically involves stimulation of hypoxia indicible factors 
(HIF)-1 and HIF-2.193 In the kidney, the primary form of HIF expressed in the 
tubules and interstitial cells is HIF-1α whereas HIF-2α is identified in mesangial 
cells, endothelial cells and fibroblasts. The HIF α-subunits are degraded by an 
oxygen dependent mechanism. This means that in periods of hypoxia HIF-α 
subunits accumulate and form heterodimers with HIF-β subunits. These 
heterodimers are able to bind to hypoxia response elements associated with key 
genes that counteract the effects of hypoxia e.g. erythropoietin, vascular 
endothelial growth factor (VEGF) which stimulates angiogenesis, heme 
oxygenase which is involved in heme metabolism, nitric oxide synthase and 
cyclo-oxygenase-2 which both have vasodilator properties.193,194,195 
 
Hypoxia itself has also been shown to be a fibrogenic stimulus to tubular 
epithelial cells, fibrocytes and endothelial cells.196 Hypoxia has been shown to 
stimulate tubular epithelial cells to undergo epithelial to mesenchymal transition 
and activate fibroblasts to increase production of ECM.197,198 Some tubular 
epithelial cells that are exposed to hypoxia develop mitochondrial derangements 
that result ultimately in cellular apoptosis. A secondary consequence of loss of 
normal renal parenchyma is a decrease in the availability of fibroblasts for the 
production of erythropoietin, which later in the disease course of CKD may result 
in anaemia. Anaemia in CKD may therefore also contribute to reduced oxygen 
delivery and hypoxia. Overall, therefore the haemodynamic and structural 
lesions that occur in CKD, contribute and promote hypoxia which is in itself is a 
driving factor contributing to renal fibrosis and generating a vicious cycle for 
disease progression (Figure 5).192 
 
In cats there is relatively little information directly relating to hypoxia and it’s 
association with the development and progression of CKD. Epidemiological 
studies have identified packed cell volume and anaemia as being risk factors for 
the survival of cats with CKD and anaemia is clinically appreciated to contribute 
to reduction in quality of life.24,199 In a more recent study, low packed cell volume 
was an independent predictor of progression of CKD in cats with IRIS stage 2 
CKD.40 Together these studies give us preliminary evidence that anaemia, which 
could certainly contribute to renal hypoxia, is a negative prognostic indicator in 
terms of progression of disease and survival.  
 
More recently studies have evaluated urinary VEGF: creatinine concentrations as 
a method of assessing response to hypoxia within the kidney. Results from these 
studies so far have been conflicting. A study by Habenicht and colleagues 
demonstrated significantly lower urinary VEGF:creatinine ratio in cats with CKD 
compared to healthy controls.200 This could be hypothesized to suggest 
inadequate response of the kidney to the hypoxic environment. Further work is 
necessary to clarify the extent to which plasma VEGF concentrations might 
contribute to urinary VEGF concentrations and to establish further robust 
markers that may be informative in terms of the role of hypoxia in the 
progression of CKD in cats.  
 
Oxidative stress 
Renal oxidative stress occurs when there is an imbalance between the 
production of reactive oxygen species (ROS; e.g. superoxide, hydroxyl radical and 
hydrogen peroxide)) and availability of anti-oxidant defense mechanisms (e.g. 
superoxide dismutase, catalase, glutathione peroxidase, and glutathione). ROS 
are highly reactive molecules, which can cause damage to DNA, lipid, protein, 
carbohydrate resulting ultimately in structural and functional cellular damage 
that leads to apoptosis and necrosis, stimulating inflammation and fibrosis. This 
imbalance is a situation that is referred to as oxidative stress.201 
 
Renal cells, particularly tubular cells, have a high metabolic activity and 
therefore have a high production rate of ROS. The major site of production of 
ROS is the mitochondria although endoplasmic reticulum, peroxisome and 
lysosomes may also contribute.202 Oxidative stress occurs in CKD when 
hyperfiltration and hyperfunctioning of remaining nephrons leads to increased 
production of ROS which influence downstream cellular signaling pathways in 
the kidney to promote renal cell apoptosis, cellular senescence, a decrease in the 
regenerative capacity of the cells and fibrosis.89,203 In particular ROS have been 
shown to stimulate NFκβ which is integral in cellular pathways that promote 
fibrosis. These factors have deleterious effects in terms of both renal disease 
progression and reducing renal function. Other factors such as aging, 
proteinuria, RAAS activation and angiotensin II, hyperphosphataemia, 
inflammation, regions of ischaemia and hypoxia, and uremic toxins can also 
contribute to the generation of ROS.201,204  
 
Assessment of oxidative stress in clinical patients is challenging and evaluation 
of biomarkers for oxidative stress is often used in place of direct assessment. 
These biomarkers may be informative in terms of lipid peroxidation (e.g. 
Isoprostanes, malondialdehyde, thiobarbituric acid reactive substances), protein 
oxidation (e.g. protein carbonyls, advanced glycation end products, oxidized low-
density lipoproteins), direct measurement of ROS (e.g. hydrogen peroxide, DNA 
or RNA damage) or may be through evaluation of antioxidant mechanisms (e.g. 
catalase, glutathione, reduced-oxidized glutathione (GSH:GSSH), glutathione 
perosxidase, superoxide dismutase).201 In human medicine, studies have shown 
increase in oxidative stress markers with advancing stage of CKD.205,206 However, 
the response to provision of antioxidants (e.g. α-tochopherol, ω-3 fatty acids, n-
acetyl cysteine, allopurinol, co-enzyme Q10) has been variable and a recent 
Cochrane review found no evidence that anti-oxidant therapy could reduce death 
or cardiovascular disease in human patients with CKD.206 The study did suggest 
that anti-oxidant therapy may lead to reduced serum creatinine and may 
therefore reduce the risk of progression to end stage renal disease and there was 
no evidence that supplementing with anti-oxidants was harmful. However, the 
review was based on few studies and overall a low event rate. The conclusion of 
this Cochrane review was therefore insufficient evidence to support routine use 
of anti-oxidant therapy at this time although there was sufficient evidence to 
support that further studies should be performed to explore the potentially 
beneficial effects of anti-oxidant therapy.206 
 
There have been few studies to date that have explored oxidative stress in 
relation to feline CKD.207 Two studies have attempted to evaluate oxidative 
stress in cats with CKD using different methods. A study by Keegan and 
colleagues, evaluated superoxide dismutase, antioxidant capacity, GSH:GSSG 
ratio, neutrophil phagocytosis and oxidative burst in cats with CKD and age 
matched control cats. Results from this study indicated that cats with CKD had 
significantly higher GSH:GSSG ratios and significantly reduced antioxidant 
capacity.208 There was no significant difference in superoxide dismuatase activity 
between groups whilst neutrophil burst was significantly higher in the CKD 
cats.208 Together these results were interpreted as evidence that anti-oxidant 
mechanisms are activated in cats with CKD. Krofic Zel and colleagues measured 
selenium concentrations, plasma and erythrocyte glutathione peroxidase activity 
and total plasma antioxidant capacity. Selenium concentrations were 
investigated because selenium is an integral component of glutathione 
peroxidase. This study identified that IRIS stage 4 cats had significantly higher 
plasma glutathione peroxidase activity but that there was no significant different 
in the other markers either amongst IRIS stage or between CKD and control 
cats.209 These results suggest that at stage 4 CKD cats may still be able to induce 
anti-oxidant mechanism and that selenium deficiency does not seem to be a 
factor.ty in cats with IRIS stage 1-4 CKD and a non-age matched control group.209  
To date only one study has evaluated anti-oxidant supplementation in cats. This 
study evaluated dietary supplementation with vitamin C and E in a group of 10 
elderly cats with CKD compared to healthy non-age matched controls.210 They 
used 8-hydroxy-2’-deoxyguanosine, a product of DNA oxidation and a comet 
assay, which is a gel electrophoresis based method for measuring DNA breaks in 
eukaryotic cells. Supplementation significantly decreased DNA damage markers 
in this study providing preliminary support for anti-oxidants in cats with CKD.210 
Overall the results of these studies only begin to touch the surface in terms of the 
role of oxidative stress in cats with CKD and whether any form of anti-oxidant 
supplementation would be of benefit. Further work is required in this area 
before routine anti-oxidant supplementation in cats can be advocated.  
 
Conclusions: Given the similarities in mammalian physiology it seems likely that 
many of the pathophysiological mechanisms implicated in the development and 
progression of kidney disease from experimental and human studies are likely to 
be common and important in the cat. However, further studies are required that 
will help demonstrate the links between environmental and individual factors 
that predispose cats to CKD, perhaps optimizing the way that we provide health 
care for cats in the earlier stages of their life. An improved understanding of the 
factors associated with progression of disease and the key mediators of these 
changes may allow us to adapt our treatment strategies for cats diagnosed with 
CKD. Particularly in relation to proteinuria, RAAS activation and hypoxia further 
clinical evidence that modulating these parameters improves outcome is 
required.  
 
  
Figure Legends: 
Figure 1: Flow diagram representing the stages involved with replicative 
and stress induced cellular senescence in renal ageing.  
 
 
  
Figure 2:  Diagram giving key steps in the process of renal injury, 
myofibroblast production and interstitial inflammation and fibrosis.  
TGFβ; transforming growth factor-beta, MCP1; monocyte chemoattractant 
protein 1, CTGF; connective tissue growth factor, TNF; tumor necrosis factor, 
αSMA; alpha-smooth muscle actin, EMT; epithelial to mesenchymal transition, 
PDGF; platelet derived growth factor, FGF2; fibroblast growth factor 2, Ang II; 
angiotensin II.   
 
  
Figure 3: Diagram exploring the origin of myofibroblasts during the time-
line of renal injury.  
 
αSMA; alpha-smooth muscle actin. 
 
  
Figure 4: Flow diagram of the effects of the renin-angiotensin aldosterone 
system on renal fibrosis and progression of kidney disease 
ACE; angiotensin converting enzyme 1, ACE2; angiotensin converting enzyme 2, 
Ang I; angiotensin 1, Ang II; angiotensin II, Ang1-7; angiotensin 1-7, Ang 1-9; 
angiotensin 1-9, NFκβ; nuclear factor kappa beta, TGFβ; transforming growth 
factor- beta.  
 
 
  
Figure 5: The role of hypoxia in progression of chronic kidney disease 
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